Profusa Inc
Research Profusa Inc (PFSA) on Bullrun: market cap USD 171.99K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPFSA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 171.99K
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.76M
- Free cash flow-USD 2.71M
Valuation Snapshot
latest market cap is USD 171.99K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 35.82M | -USD 16.26M | n/a | -107.01 | USD 1.78M | USD 14.82M | -USD 26.66M |
| FY2024 | USD 100.00K | -USD 9.23M | -USD 2.07M | n/a | -357.14 | USD 191.00K | USD 48.21M | -USD 119.21M |
| FY2023 | USD 0 | USD 1.16M | -USD 4.40M | n/a | 0.12 | USD 4.52K | USD 200.00K | -USD 110.00M |
| FY2022 | USD 0 | USD 7.17M | -USD 7.70M | n/a | 0.3 | USD 193.49K | USD 31.03M | -USD 619.48K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 171.99K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.71M | n/a | n/a | n/a |
About Profusa Inc
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Profusa Inc's market cap?
Profusa Inc's market capitalization is USD 171.99K.
What does Profusa Inc do?
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.